ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Acupuncture for Irritable Bowel Syndrome (IBS)

This study has been completed.

Sponsors and Collaborators: National Center for Complementary and Alternative Medicine (NCCAM)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by: National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier: NCT00093327
  Purpose

The purpose of this study is to determine whether acupuncture is effective in reducing the symptoms of irritable bowel syndrome (IBS).


Condition Intervention Phase
Irritable Bowel Syndrome
Procedure: Acupuncture
Phase II

MedlinePlus related topics:   Acupuncture   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:   Acupuncture for Irritable Bowel Syndrome (IBS) Trial

Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):

Estimated Enrollment:   287
Study Start Date:   September 2003
Estimated Study Completion Date:   April 2006

Detailed Description:

IBS is a disorder that affects colon functioning. Although it does not cause permanent harm or lead to more serious conditions, IBS can cause a great deal of discomfort and distress. The effectiveness of acupuncture in treating various conditions has been investigated in numerous studies. However, little is known about acupuncture's efficacy in treating IBS. This study will determine whether acupuncture can alleviate the symptoms of IBS, including pain relief with defecation, changes in stools, and changes in the frequency of bowel movements.

Participants in this study will be randomly assigned to receive bi-weekly sessions of either active or placebo acupuncture or no treatment for 6 weeks. Study visits will occur at study start, Week 3, and Week 6 (study completion). At each study visit, blood collection will occur to measure levels of cortisol, a stress hormone associated with IBS. Participants will also complete questionnaires about their IBS symptoms. Selected participants will be interviewed at each visit, in order to determine whether participants' interpretations and understanding of IBS influences their response to treatment. Any subject who does not receive active acupuncture during the trial is eligible for 6 free acupuncture treatments after the study is over.

  Eligibility
Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Irritable bowel syndrome of moderate severity for at least 12 weeks within 1 year prior to study entry
  • Colonoscopy or flexible sigmoidoscopy/air contrast barium enema within 5 years prior to study entry
  • Able to walk
  • Able and willing to cooperate with the study
  • Sufficient knowledge of English to be able to participate in the study

Exclusion Criteria:

  • Medications that affect the gastrointestinal tract or visceral sensation, unless the participant is on a stable dose for at least 1 month prior to study entry and for the duration of the study
  • History of severe or intractable IBS
  • History of acupuncture treatment
  • Score between 37 and 150 on the Functional Bowel Disorder Severity Index (FBDSI)
  • Any concomitant bowel problem that would interfere with the study
  • History of laxative abuse
  • Abdominal surgery, with the exception of uncomplicated removal of the appendix, uterus, or gallbladder more than 6 months prior to study entry
  • History of metabolic or inflammatory disease that may affect bowel movement
  • History of significant psychiatric, neurological, metabolic, hepatic, renal, infectious, hematological, cardiovascular, gastrointestinal, or pulmonary illness. Participants who are stable for more than 1 year with conditions that will not interfere with the study are not excluded.
  • History of drug or alcohol abuse within 2 years prior to study entry
  • Positive for opiates at the initial visit drug screen
  • Abnormal vital signs, physical examination results, or clinical laboratory values, unless these abnormalities are judged to be clinically insignificant
  • Pregnancy or breastfeeding
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00093327

Locations
United States, Massachusetts
Beth Israel Deaconess Medical Center, General Clinical Research Center    
      Boston, Massachusetts, United States, 02215

Sponsors and Collaborators

Investigators
Principal Investigator:     Ted Kaptchuk, OMD     Beth Israel Deaconess Medical Center    
  More Information


Study ID Numbers:   R01 AT001414-01
First Received:   October 6, 2004
Last Updated:   August 17, 2006
ClinicalTrials.gov Identifier:   NCT00093327
Health Authority:   United States: Federal Government

Study placed in the following topic categories:
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Irritable Bowel Syndrome
Intestinal Diseases
Colonic Diseases, Functional

Additional relevant MeSH terms:
Pathologic Processes
Disease
Syndrome

ClinicalTrials.gov processed this record on October 09, 2008




Links to all studies - primarily for crawlers